Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anjiarun is a proprietary hospital-made traditional Chinese medicine (TCM) preparation developed by the Sichuan Provincial People's Hospital, specifically for the treatment of ankylosing spondylitis (AS). Formulated as granules, it contains a blend of herbal ingredients, most notably *Tripterygium wilfordii* Hook. f., which is well-documented for its potent anti-inflammatory and immunosuppressive properties. The drug is designed to reduce joint inflammation, alleviate pain, and improve spinal mobility by modulating the immune response and inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. It is officially registered as a hospital preparation in Sichuan Province, China, under the approval number 川药制字Z20100004, and has been used clinically within the hospital's rheumatology department for several years.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anjiarun.